NeuroOne Medical Technologies マネジメント

マネジメント基準チェック /34

NeuroOne Medical Technologiesの CEO はDave Rosaで、 Jul2017年に任命され、の在任期間は 7.33年です。の年間総報酬は$ 989.56Kで、 51.2%給与と48.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.38%を直接所有しており、その価値は$ 289.84K 。経営陣と取締役会の平均在任期間はそれぞれ4.7年と6.7年です。

主要情報

Dave Rosa

最高経営責任者

US$989.6k

報酬総額

CEO給与比率	51.2%
CEO在任期間	7.3yrs
CEOの所有権	1.4%
経営陣の平均在職期間	4.7yrs
取締役会の平均在任期間	6.7yrs

経営陣の近況

Recent updates

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Dec 16

Can NeuroOne Medical Technologies (NASDAQ:NMTC) Afford To Invest In Growth?

Jul 25

Here's Why We're Watching NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Situation

Apr 11

We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully

Sep 15

NeuroOne rallies on receiving $3.5M in accelerated milestone payment from Zimmer Biomet

Aug 03

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Jun 02

Companies Like NeuroOne Medical Technologies (NASDAQ:NMTC) Could Be Quite Risky

Dec 18

NeuroOne: Thin Film Electrodes For Diagnosis And Treatment Of Neurological Conditions

Nov 19

Will NeuroOne Medical Technologies (NASDAQ:NMTC) Spend Its Cash Wisely?

Sep 04

We're Not Very Worried About NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Rate

May 27

CEO報酬分析

NeuroOne Medical Technologies の収益と比較して、Dave Rosa の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$12m
Mar 31 2024	n/a	n/a	-US$13m
Dec 31 2023	n/a	n/a	-US$13m
Sep 30 2023	US$990k	US$507k	-US$12m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$9m
Dec 31 2022	n/a	n/a	-US$9m
Sep 30 2022	US$1m	US$472k	-US$10m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$11m
Dec 31 2021	n/a	n/a	-US$11m
Sep 30 2021	US$2m	US$411k	-US$10m
Jun 30 2021	n/a	n/a	-US$8m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	n/a	n/a	-US$11m
Sep 30 2020	US$1m	US$404k	-US$14m
Jun 30 2020	n/a	n/a	-US$14m
Mar 31 2020	n/a	n/a	-US$9m
Dec 31 2019	n/a	n/a	-US$10m
Sep 30 2019	US$558k	US$392k	-US$7m
Jun 30 2019	n/a	n/a	-US$8m
Mar 31 2019	n/a	n/a	-US$7m
Dec 31 2018	n/a	n/a	-US$6m
Sep 30 2018	US$417k	US$288k	-US$7m
Jun 30 2018	n/a	n/a	-US$6m
Mar 31 2018	n/a	n/a	-US$6m
Dec 31 2017	US$496k	US$357k	-US$5m

報酬と市場: Daveの総報酬 ($USD 989.56K ) は、 US市場 ($USD 649.07K ) の同規模の企業の平均を上回っています。

報酬と収益: Daveの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Dave Rosa (60 yo)

7.3yrs

在職期間

US$989,558

報酬

Mr. David A. Rosa, also known as Dave, M.D., serves as an Independent Director of BioRestorative Therapies, Inc. since November 4, 2021. He serves as Director of BlinkTBI, Inc. since July 2023. He serves a...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David Rosa	President	7.3yrs	US$989.56k	1.38% $ 289.8k
Ronald McClurg	Chief Financial Officer	3.8yrs	US$390.16k	0.37% $ 77.5k
Steven Mertens	Chief Technology Officer	5.6yrs	US$457.71k	0.16% $ 33.4k
Mark Christianson	Co-Founder	no data	US$260.85k	0.85% $ 178.8k
Christopher Volker	Chief Operating Officer	less than a year	データなし	0.24% $ 51.1k
Hijaz Haris	Vice President of Marketing	no data	データなし	データなし

4.7yrs

平均在職期間

60.5yo

平均年齢

経験豊富な経営陣: NMTCの経営陣は経験豊富であると考えられます ( 4.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
David Rosa	President	7.3yrs	US$989.56k	1.38% $ 289.8k
Jeffrey Mathiesen	Independent Director	7.3yrs	US$120.49k	0.27% $ 56.7k
Paul Buckman	Independent Chairman of the Board	7.3yrs	US$168.99k	0.35% $ 74.2k
Edward Andrle	Independent Director	4.8yrs	US$118.99k	0.20% $ 41.4k
Robert Gross	Member of Scientific Advisory Board	3.4yrs	データなし	データなし
Greg Worrell	Chairman of Scientific Advisory Board	no data	データなし	データなし
Jamie Van Gompel	Member of Scientific Advisory Board	no data	データなし	データなし
Gregory Esper	Member of Scientific Advisory Board	no data	データなし	データなし
Justin Williams	Member of Scientific Advisory Board	no data	データなし	データなし
Kip Ludwig	Member of Scientific Advisory Board	6.2yrs	データなし	データなし

6.7yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: NMTCの取締役会は経験豊富であると考えられます ( 6.7年の平均在任期間)。

NeuroOne Medical Technologies マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Insufficient new directors

NeuroOne Medical Technologies Corporation, Annual General Meeting, Mar 14, 2024

Chief Operating Officer recently bought US$105k worth of stock

Co-Founder notifies of intention to sell stock

NeuroOne Medical Technologies Corporation Appoints Christopher R. Volker as Chief Operating Officer

Chief Financial Officer recently bought US$50k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.10 loss per share (vs US$0.20 loss in 3Q 2023)

NeuroOne Medical Technologies Corporation to Report Q3, 2024 Results on Aug 14, 2024

NeuroOne Medical Technologies Corporation announced that it has received $2.650001 million in funding

NeuroOne Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

NeuroOne Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Insufficient new directors

NeuroOne® Announces First in Human Ablations Completed with OneRF™ Ablation System

Neuroone Medical Technologies Corporation Receives Approval of ICD-10 Procedure Code for sEEG RF Ablation

Second quarter 2024 earnings released: US$0.11 loss per share (vs US$0.21 loss in 2Q 2023)

NeuroOne Medical Technologies Corporation to Report Q2, 2024 Results on May 14, 2024

Price target decreased by 25% to US$2.00

NeuroOne Medical Technologies Corporation Initiates Limited Commercial Launch of OneRF Ablation System

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

NeuroOne Medical Technologies Corporation to Report Q1, 2024 Results on Feb 13, 2024

NeuroOne Medical Technologies Corporation, Annual General Meeting, Mar 14, 2024

Chief Operating Officer recently bought US$105k worth of stock

Co-Founder notifies of intention to sell stock

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 27% to US$2.67

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

NeuroOne Medical Technologies Corporation Receives FDA 510(K) Clearance to Market its OneRF(TM) Ablation System

NeuroOne Medical Technologies Corporation to Report Q4, 2023 Results on Dec 14, 2023

NeuroOne Medical Technologies Corporation Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe

NeuroOne Medical Technologies Corporation Appoints Christopher R. Volker as Chief Operating Officer

NeuroOne Medical Technologies Corporation Provides Progress Update on FDA 510(k) Submission for OneRF™? Ablation System

Chief Financial Officer recently bought US$50k worth of stock

Consensus revenue estimates increase by 13%, EPS downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

NeuroOne Medical Technologies Corporation to Report Q3, 2023 Results on Aug 14, 2023

New major risk - Share price stability

Can NeuroOne Medical Technologies (NASDAQ:NMTC) Afford To Invest In Growth?

NeuroOne Medical Technologies Corporation Submits 510(K) Application to FDA for OneRF™ Ablation System

NeuroOne Medical Technologies Corporation Announces First Clinical Case Using Evo® sEEG Electrode in Robotic Neurosurgery

Consensus revenue estimates increase by 13%

Second quarter 2023 earnings released: US$0.21 loss per share (vs US$0.19 loss in 2Q 2022)

NeuroOne Medical Technologies Corporation to Report Q2, 2023 Results on May 11, 2023

Here's Why We're Watching NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Situation

Consensus revenue estimates decrease by 41%, EPS upgraded

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

NeuroOne Medical Technologies Corporation to Report Q1, 2023 Results on Feb 14, 2023

NeuroOne Medical Technologies Corporation, Annual General Meeting, Mar 16, 2023

Consensus revenue estimates increase by 154%

NeuroOne Medical Technologies Corporation Auditor Raises 'Going Concern' Doubt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

NeuroOne Successfully Completes Feasibility Study with its OneRF Ablation System

Price target decreased to US$2.63

NeuroOne Medical Technologies Corporation Receives U.S. Food and Drug Administration 510(K) Clearance to Market Its Evo sEEG System for Less Than 30 Day Use

We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeuroOne Medical Technologies Corporation Submits Special 510(k) to FDA for Evo sEEG Electrode

Consensus estimates of losses per share improve by 13%

NeuroOne rallies on receiving $3.5M in accelerated milestone payment from Zimmer Biomet

NeuroOne Announces First Clinical Case Using Evo sEEG Electrode

Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?

NeuroOne Medical Technologies Corporation Provides Evo's EEG Update

Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.21 loss in 2Q 2021)

NeuroOne Medical Technologies Corporation to Report Q2, 2022 Results on May 12, 2022

NeuroOne Medical Technologies Corporation, Annual General Meeting, May 31, 2022

Price target decreased to US$2.63

NeuroOne Medical Technologies Corporation Releases Successful Completion of Long-Term Stimulation Tests for Its Novel Thin Film Platform Electrode Technology

First quarter 2022 earnings: EPS misses analyst expectations

NeuroOne® Medical Technologies Corporation Releases Successful Long-Term Recording Test Data for Its Novel Thin Film Platform Electrode Technology

Companies Like NeuroOne Medical Technologies (NASDAQ:NMTC) Could Be Quite Risky

NeuroOne: Thin Film Electrodes For Diagnosis And Treatment Of Neurological Conditions

NeuroOne® Medical Technologies Corporation Announces Successful Completion of Feasibility Study for Ablation Electrode

NeuroOne Medical Technologies Corporation Receives FDA 510(k) Clearance for its Evo sEEG Electrode

Will NeuroOne Medical Technologies (NASDAQ:NMTC) Spend Its Cash Wisely?

Insider recently sold US$80k worth of stock

マネジメント基準チェック /34